Crinetics Pharmaceuticals Inc
CRNX48.380USD
-0.330-0.68%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
4.57BCap. mercado
PérdidaP/E TTM
Más Datos de Crinetics Pharmaceuticals Inc Compañía
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Información de Crinetics Pharmaceuticals Inc
Símbolo de cotizaciónCRNX
Nombre de la empresaCrinetics Pharmaceuticals Inc
Fecha de salida a bolsaJul 18, 2018
Director ejecutivoStruthers (R. Scott)
Número de empleados437
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 18
Dirección6055 Lusk Blvd.
CiudadSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92121
Teléfono18584506464
Sitio Webhttps://www.crinetics.com/
Símbolo de cotizaciónCRNX
Fecha de salida a bolsaJul 18, 2018
Director ejecutivoStruthers (R. Scott)
Ejecutivos de Crinetics Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
116.15K
+6.32%
Dr. Stephen F. Betz, Ph.D.
Dr. Stephen F. Betz, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
99.28K
-8.58%
Mr. Tobin C. (Toby) Schilke
Mr. Tobin C. (Toby) Schilke
Chief Financial Officer
Chief Financial Officer
52.00K
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Independent Director
Independent Director
16.30K
+73.40%
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Independent Director
Independent Director
16.30K
+73.40%
Dr. Weston A. Nichols, Ph.D.
Dr. Weston A. Nichols, Ph.D.
Independent Director
Independent Director
16.30K
+73.40%
Ms. Stephanie S. Okey
Ms. Stephanie S. Okey
Independent Director
Independent Director
16.30K
+73.40%
Dr. Dana Pizzuti, M.D.
Dr. Dana Pizzuti, M.D.
Chief Medical and Development Officer
Chief Medical and Development Officer
--
--
Ms. Isabel Kalofonos
Ms. Isabel Kalofonos
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Wendell Wierenga, Ph.D.
Dr. Wendell Wierenga, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
116.15K
+6.32%
Dr. Stephen F. Betz, Ph.D.
Dr. Stephen F. Betz, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
99.28K
-8.58%
Mr. Tobin C. (Toby) Schilke
Mr. Tobin C. (Toby) Schilke
Chief Financial Officer
Chief Financial Officer
52.00K
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Independent Director
Independent Director
16.30K
+73.40%
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Independent Director
Independent Director
16.30K
+73.40%
Dr. Weston A. Nichols, Ph.D.
Dr. Weston A. Nichols, Ph.D.
Independent Director
Independent Director
16.30K
+73.40%
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
13.21%
The Vanguard Group, Inc.
9.64%
Wellington Management Company, LLP
8.83%
BlackRock Institutional Trust Company, N.A.
7.01%
Driehaus Capital Management, LLC
6.83%
Otro
54.47%
Accionistas
Accionistas
Proporción
Fidelity Management & Research Company LLC
13.21%
The Vanguard Group, Inc.
9.64%
Wellington Management Company, LLP
8.83%
BlackRock Institutional Trust Company, N.A.
7.01%
Driehaus Capital Management, LLC
6.83%
Otro
54.47%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
52.18%
Investment Advisor/Hedge Fund
43.98%
Hedge Fund
14.23%
Individual Investor
2.02%
Venture Capital
2.01%
Research Firm
1.94%
Private Equity
1.16%
Bank and Trust
0.57%
Pension Fund
0.49%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
525
110.25M
122.53%
+10.44K
2025Q3
543
110.25M
126.46%
+2.35M
2025Q2
527
106.83M
124.47%
+1.78M
2025Q1
508
105.21M
122.53%
-8.81M
2024Q4
492
102.43M
107.05%
+15.47M
2024Q3
460
87.33M
121.15%
+1.87M
2024Q2
441
84.74M
119.85%
+1.98M
2024Q1
399
82.75M
110.72%
-4.21M
2023Q4
366
73.18M
119.64%
+1.80M
2023Q3
342
72.45M
96.67%
+14.82M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Fidelity Management & Research Company LLC
12.42M
13.19%
+97.46K
+0.79%
Jun 30, 2025
The Vanguard Group, Inc.
9.24M
9.81%
-55.47K
-0.60%
Jun 30, 2025
Wellington Management Company, LLP
5.81M
6.17%
-1.08M
-15.73%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.50M
6.9%
-274.52K
-4.05%
Jun 30, 2025
Driehaus Capital Management, LLC
6.40M
6.8%
+160.12K
+2.57%
Jun 30, 2025
Farallon Capital Management, L.L.C.
5.63M
5.97%
+979.00K
+21.07%
Aug 29, 2025
T. Rowe Price Associates, Inc.
5.49M
5.83%
+472.19K
+9.40%
Jun 30, 2025
EcoR1 Capital, LLC
4.29M
4.55%
--
--
Jun 30, 2025
Janus Henderson Investors
3.41M
3.62%
-14.12K
-0.41%
Jun 30, 2025
Paradigm BioCapital Advisors LP
2.34M
2.49%
+397.38K
+20.42%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
State Street SPDR S&P Pharmaceuticals ETF
3.24%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.92%
Tema Heart & Health ETF
1.9%
ALPS Medical Breakthroughs ETF
1.79%
iShares U.S. Pharmaceuticals ETF
1.51%
First Trust Multi-Manager Small Cap Opportunities ETF
1.31%
Virtus LifeSci Biotech Clinical Trials ETF
0.92%
ProShares Ultra Nasdaq Biotechnology
0.52%
Invesco Nasdaq Biotechnology ETF
0.4%
iShares Biotechnology ETF
0.34%
Ver más
State Street SPDR S&P Pharmaceuticals ETF
Proporción3.24%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción2.92%
Tema Heart & Health ETF
Proporción1.9%
ALPS Medical Breakthroughs ETF
Proporción1.79%
iShares U.S. Pharmaceuticals ETF
Proporción1.51%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporción1.31%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.92%
ProShares Ultra Nasdaq Biotechnology
Proporción0.52%
Invesco Nasdaq Biotechnology ETF
Proporción0.4%
iShares Biotechnology ETF
Proporción0.34%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Crinetics Pharmaceuticals Inc?
Los cinco principales accionistas de Crinetics Pharmaceuticals Inc son:
Fidelity Management & Research Company LLC posee 12.42M acciones, lo que representa el 13.19% del total de acciones.
The Vanguard Group, Inc. posee 9.24M acciones, lo que representa el 9.81% del total de acciones.
Wellington Management Company, LLP posee 5.81M acciones, lo que representa el 6.17% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 6.50M acciones, lo que representa el 6.90% del total de acciones.
Driehaus Capital Management, LLC posee 6.40M acciones, lo que representa el 6.80% del total de acciones.
Fidelity Management & Research Company LLC posee 12.42M acciones, lo que representa el 13.19% del total de acciones.
The Vanguard Group, Inc. posee 9.24M acciones, lo que representa el 9.81% del total de acciones.
Wellington Management Company, LLP posee 5.81M acciones, lo que representa el 6.17% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 6.50M acciones, lo que representa el 6.90% del total de acciones.
Driehaus Capital Management, LLC posee 6.40M acciones, lo que representa el 6.80% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Crinetics Pharmaceuticals Inc?
Los tres principales tipos de accionista de Crinetics Pharmaceuticals Inc son:
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
Wellington Management Company, LLP
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.
Wellington Management Company, LLP
¿Cuántas instituciones poseen acciones de Crinetics Pharmaceuticals Inc (CRNX)?
A fecha de 2025Q4, 525 instituciones poseen acciones de Crinetics Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 110.25M, lo que representa el 122.53% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -3.93%.
¿Cuál es la mayor fuente de ganancias de Crinetics Pharmaceuticals Inc?
El --, el segmento empresarial -- generó la ganancia más alta para Crinetics Pharmaceuticals Inc, ascendiendo a -- y representando el --% de la ganancia total.
